SWI/SNF-B Inhibitors
Chemical inhibitors of SWI/SNF-B can employ various strategies to disrupt the function of this protein complex involved in chromatin remodeling. Trichostatin A, a histone deacetylase inhibitor, can alter chromatin structure and thus inhibit SWI/SNF-B by reducing the accessibility of DNA for the protein complex to act upon. Similarly, Mithramycin A directly binds to DNA sequences, which can obstruct the binding of SWI/SNF-B to chromatin and hinder its remodeling capabilities. Actinomycin D also intercalates into DNA, which can block the DNA binding sites that are essential for SWI/SNF-B's function. Chemicals such as Chloroquine and Concanamycin A affect the endosomal-lysosomal pathway, which can result in the improper recycling and localization of SWI/SNF-B, leading to a compromised chromatin remodeling function. Disturbance in the cellular recycling processes can prevent the proper assembly or maintenance of SWI/SNF-B at functional sites within chromatin.
Proteasome inhibitors like MG-132 and Bortezomib can inhibit SWI/SNF-B by stabilizing proteins that negatively regulate the complex, thereby inhibiting its action on chromatin. Etoposide and Camptothecin cause DNA damage and can inhibit SWI/SNF-B through the activation of DNA damage response pathways that may sequester the complex away from its chromatin targets or directly interfere with its activity. Bisphenol A, by influencing the epigenetic landscape, can lead to changes that negatively impact the remodeling activity of SWI/SNF-B. Sirolimus, an mTOR inhibitor, can reduce the cellular resources and energy required for the ATP-dependent chromatin remodeling activities of SWI/SNF-B. Lastly, Rocaglamide, by inhibiting translation, can reduce the synthesis of crucial components or cofactors necessary for the functional activity of SWI/SNF-B, further inhibiting its ability to remodel chromatin effectively. Each chemical targets specific pathways or cellular processes that are integral to the proper functioning of SWI/SNF-B, leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can lead to changes in chromatin structure, potentially inhibiting SWI/SNF-B by altering the accessibility of DNA to the protein complex and its ability to remodel chromatin. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is known to inhibit lysosomal activity and could potentially disrupt the recycling of SWI/SNF-B components, impairing the assembly or function of the SWI/SNF-B complex. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A binds to G-C rich DNA sequences and could inhibit SWI/SNF-B by preventing its binding to chromatin, thus obstructing the remodeling activity of the complex. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A, as a V-ATPase inhibitor, disrupts endosomal-lysosomal acidification, which can inhibit the recycling and proper localization of SWI/SNF-B, thereby impairing its function. | ||||||
Bisphenol A | 80-05-7 | sc-391751 sc-391751A | 100 mg 10 g | $300.00 $490.00 | 5 | |
Bisphenol A, an endocrine disruptor, can influence gene expression and chromatin structure, potentially inhibiting SWI/SNF-B by altering the epigenetic landscape the complex acts upon. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that could inhibit SWI/SNF-B by preventing the degradation of regulatory proteins that control SWI/SNF-B activity, leading to an accumulation of repressive factors that inhibit the complex. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide induces DNA damage and can inhibit SWI/SNF-B by triggering DNA damage response pathways, leading to the recruitment of repair proteins that could sterically hinder SWI/SNF-B function. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D intercalates into DNA and could inhibit SWI/SNF-B by blocking the DNA binding sites necessary for the remodeling activity of the complex. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits topoisomerase I, leading to DNA damage and potentially inhibiting SWI/SNF-B by activating DNA damage responses that compete with or block the complex's access to chromatin. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that could inhibit SWI/SNF-B by stabilizing negative regulators of the complex, thus preventing its action on chromatin remodeling. | ||||||